GlassScriptPhysician profile
Shaun S Bath
NPI 1154688380
$1,606.78
in general payments reported to CMS, 2019-2025
21 companies · $124 in 2025
The $124 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $50.53 · 2021: $302 · 2022: $105 · 2023: $458 · 2024: $273 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $453.53 | 2019-2024 | Xarelto |
| Pfizer INC. | $186.95 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $107.34 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $100.78 | 2019-2023 | Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.10 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $86.88 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| E.R. Squibb & Sons, L.L.C. | $74.09 | 2019-2021 | |
| Novo Nordisk INC | $66.14 | 2022-2023 | |
| Melinta Therapeutics, LLC | $62.71 | 2020-2021 | |
| Stryker Corporation | $51.52 | 2025 | Clottriever Bold Catheter, Flowtriever |
| Alexion Pharmaceuticals, INC. | $43.10 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.47 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.17 | 2023 | Xifaxan |
| Inari Medical, INC. | $35.45 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbott Laboratories | $34.59 | 2024 | Cardiomems |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31.80 | 2021 | |
| Bioxcel Therapeutics, INC. | $23.81 | 2023 | Igalmi |
| Mallinckrodt Hospital Products INC. | $22.66 | 2025 | Terlivaz |
| Genzyme Corporation | $21.15 | 2024 | |
| Chiesi USA, INC. | $19.79 | 2021 | |
| Lilly USA, LLC | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun Bath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.